Gilead's Hepsera Approved To Treat Chronic Hepatitis B
By Randall Osborne
Tuesday, September 24, 2002
Less than two months after an advisory panel unanimously recommended approval of Gilead Sciences Inc.'s Hepsera (adefovir dipivoxil) for chronic hepatitis B, the FDA has given its expected nod and the company plans to ship the drug this week - with a price tag that was higher than some analysts had forecast.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.